文献速递血脂与心血管预防

FOURIER 试验:Martin/Hopkins 与 Friedewald 及超速离心法评估 LDL-C 的比较

Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.
PubMed 文献 · JAMA Cardiol · 2018-01-01

基于 FOURIER 试验 12 742 例患者的 56 624 次观测,比较 Martin/Hopkins 与 Friedewald 法估算 LDL-C 与金标准制备性超速离心(PUC)的一致性。Martin/Hopkins 与 PUC 的中位差值、偏差比例及相关性均优于 Friedewald,提示在 PCSK9 抑制剂治疗后的低 LDL-C 人群中可减少因低估导致的治疗不足。

要点

  • Martin/Hopkins 与 PUC 中位差值 -2 mg/dL,Friedewald 为 -4 mg/dL,后者存在低估。
  • Martin/Hopkins 偏差>5 mg/dL 比例 22.9%,显著低于 Friedewald 的 40.1%。
  • Martin/Hopkins 与 PUC 相关性 ρ=0.918,显著高于 Friedewald 的 ρ=0.867。

核心结论

  • 在 PCSK9 抑制剂治疗达到低 LDL-C 的患者中,Martin/Hopkins 法估算的 LDL-C 比 Friedewald 法更接近金标准 PUC。
  • Martin/Hopkins 法可能避免因 Friedewald 法低估 LDL-C 而导致的治疗不足。

研究设计与样本

  • FOURIER 为随机临床试验,比较 evolocumab 与安慰剂在 27 564 例稳定动脉粥样硬化性心血管病患者中加用他汀治疗的效果。
  • 本分析纳入 12 742 例患者,平均(SD)年龄 62.7(9.0)岁,其中女性 2885 例(22.6%)。
  • 共 56 624 次观测同时具备 Friedewald、Martin/Hopkins 和 PUC 的 LDL-C 测量值。
  • 当 Friedewald 法 LDL-C <40 mg/dL 时直接以 PUC 测量;Martin/Hopkins 法采用患者特异性甘油三酯/VLDL-C 比值估算 VLDL-C。

主要发现

  • Martin/Hopkins 与 PUC 的中位差值为 -2 mg/dL(IQR -4 至 1 mg/dL),Friedewald 为 -4 mg/dL(IQR -8 至 -1 mg/dL;P < .001)。
  • 22.9% 的 Martin/Hopkins LDL-C 值与 PUC 相差超过 5 mg/dL,2.6% 相差超过 10 mg/dL。
  • Friedewald 法相应比例分别为 40.1% 和 13.3%(P < .001),主要由于 Friedewald 法低估。
  • Martin/Hopkins 与 PUC 的相关性 ρ=0.918(95% CI 0.916-0.919),Friedewald 为 ρ=0.867(0.865-0.869),P < .001。

临床怎么用

  • 在 PCSK9 抑制剂治疗后的低 LDL-C 患者中,可优先采用 Martin/Hopkins 法估算 LDL-C 以减少低估。
  • 对 Friedewald 法估算的低 LDL-C 值应警惕低估可能,必要时结合直接测量方法评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Recent studies have shown that Friedewald underestimates low-density lipoprotein cholesterol (LDL-C) at lower levels, which could result in undertreatment of high-risk patients. A novel method (Martin/Hopkins) using a patient-specific conversion factor provides more accurate LDL-C levels. However, this method has not been tested in proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor-treated patients. OBJECTIVE: To investigate accuracy of 2 different methods for estimating LDL-C levels (Martin/Hopkins and Friedewald) compared with gold standard preparative ultracentrifugation (PUC) in patients with low LDL-C levels in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk (FOURIER) trial. DESIGN, SETTING, AND PARTICIPANTS: The FOURIER trial was a randomized clinical trial of evolocumab vs placebo added to statin therapy in 27 564 patients with stable atherosclerotic cardiovascular disease. The patients' LDL-C levels were assessed at baseline, 4 weeks, 12 weeks, 24 weeks, and every 24 weeks thereafter, and measured directly by PUC when the level was less than 40 mg/dL per the Friedewald method (calculated as non-HDL-C level - triglycerides/5). In the Martin/Hopkins method, patient-specific ratios of triglycerides to very low-density lipoprotein cholesterol (VLDL-C) ratios were determined and used to estimate VLDL-C, which was subtracted from the non-HDL-C level to obtain the LDL-C level. MAIN OUTCOMES AND MEASURES: Low-density lipoprotein cholesterol calculated by the Friedewald and Martin/Hopkins methods, with PUC as the reference method. RESULTS: For this analysis, the mean (SD) age was 62.7 (9.0) years; 2885 of the 12 742 patients were women (22.6%). A total of 56 624 observations from 12 742 patients had Friedewald, Martin/Hopkins, and PUC LDL-C measurements. The median difference from PUC LDL-C levels for Martin/Hopkins LDL-C levels was -2 mg/dL (interquartile range [IQR], -4 to 1 mg/dL) and for Friedewald LDL-C levels was -4 mg/dL (IQR, -8 to -1 mg/dL; P < .001). Overall, 22.9% of Martin/Hopkins LDL-C values were more than 5 mg/dL different than PUC values, and 2.6% were more than 10 mg/dL different than PUC levels. These were significantly less than respective proportions with Friedewald estimation (40.1% and 13.3%; P < .001), mainly because of underestimation by the Friedewald method. The correlation with PUC LDL-C was significantly higher for Martin/Hopkins vs Friedewald (ρ, 0.918 [95% CI 0.916-0.919] vs ρ, 0.867 [0.865-0.869], P < .001). CONCLUSIONS AND RELEVANCE: In patients achieving low LDL-C with PCSK9 inhibition, the Martin/Hopkins method for LDL-C estimation more closely approximates gold standard PUC than Friedewald estimation does. The Martin/Hopkins method may prevent undertreatment because of LDL-C underestimation by the Friedewald method. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01764633.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Martin SS, Giugliano RP, Murphy SA, et al. Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. JAMA Cardiol. 2018. PMID: 29898218. doi:10.1001/jamacardio.2018.1533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。